Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method
- 1 June 2004
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 6 (3) , 244-252
- https://doi.org/10.1080/14653240410006086
Abstract
Cell enrichment methods that deal with larger volumes of peripheral blood and BM are needed for increased sensitivity of detection, characterization and quantification of isolated tumor cells (ITC). This study was designed to evaluate a new procedure, the RosetteSep-Applied Imaging Rare Event (RARE) detection method, which depletes the majority of the erythrocytes and leucocytes in a peripheral blood (PB) sample, thereby negatively enriching tumor cells if present. This enrichment procedure allows for increased sensitivity, by analyzing a 5–10 fold larger volume of blood, compared with a direct immunocytochemical (ICC) technique, with minimal impact on laboratory workload. Model experiments showed comparable tumor cell recoveries between the two tested methods, both in PB and BM. Clinical samples were evaluated using paired PB and BM samples from 95 carcinoma patients. Analysis ofPB results showed that 25.3% had ≥ 1 tumor cell detected by the RARE procedure, compared with 5.2% after direct ICC analysis, analyzing a 10-fold larger volume by the RARE procedure. The direct ICC analysis of BM from the same patients revealed 16.8% positive. The ITC detection differed both quantitatively and qualitatively between BM and PB, as samples with high numbers of ITC in BM were still negative in PB. The clinical significance of ITC in blood still needs to be established. However, the easy access of peripheral blood, and the increased sensitivity obtained by increasing the sample volume with the RARE procedure, suggests that the value of peripheral blood analysis should be tested in parallel in studies where ITC detection in BM is performed.Keywords
This publication has 21 references indexed in Scilit:
- Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast CancerJournal of Clinical Oncology, 2003
- Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosisCancer, 2002
- Epithelial Cells in Bone Marrow of Breast Cancer Patients at Time of Primary Surgery: Clinical Outcome During Long-Term Follow-UpJournal of Clinical Oncology, 2001
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000
- Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separationInternational Journal of Cancer, 1998
- Immunomagnetic Techniques for the Enrichment and Detection of Isolated Breast Carcinoma Cells in Bone Marrow and Peripheral BloodJournal of Hematotherapy, 1997
- Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: Prognostic Value in Comparison With Nodal StatusJNCI Journal of the National Cancer Institute, 1996
- Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastasesThe Lancet, 1996
- Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upBritish Journal of Cancer, 1994
- Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patientsThe Lancet, 1992